Company intelligence / Profile preview

Neuralert Technologies

Philadelphia, Pennsylvania, United Statesneuralert.co ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

The company’s wristband device has been clinically proven in multiple trials to detect strokes within 15 minutes—up to ten times faster than current standard of care. It received FDA Breakthrough Device designation in 2021. An IRB-approved clinical study with over 300 patients enrolled as of early 2024 aims to further validate the technology. The product has achieved minimum viable product status but does not appear to be commercially launched yet.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy (wearable medical device for stroke detection)
Industry: Physiological Monitoring

Partnerships

University of PennsylvaniaUniversity City Science CenterNextFab Hardware AcceleratorInteprodM Squared

Beyond the preview

Go deeper on Neuralert Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuralert Technologies.

Explore the full profile